Medac 
Welcome,         Profile    Billing    Logout  
 9 Products   120 Diseases   9 Products   46 Trials   2133 News 


«12...18192021222324252627282930»
  • ||||||||||  Ovastat (treosulfan) / Medac, busulfan / Generic mfg.
    [VIRTUAL] HEMATOPOETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1421;    
    The conditioning regimens were predominantly based on myeloablative protocols that consisted of treosulfan or busulfan with weight-based dosages, except for two twin cases wherein a non-myeloablative regimen was used in their first transplantation. Our data show that HSCT for patients with CD40 ligand deficiency is a potentially effective treatment for long-term disease control.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR αβ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1414;    
    Most patients (74.1%) received reduced-toxicity myeloablative conditioning consisting of treosulfan (n=13) or busulfan (n=6), fludarabine and thiotepa...Fourteen patients received rituximab to reduce the risk of EBV-related posttransplantation lymphoproliferative disease...Graft versus host disease (GVHD) prophylaxis consisted of cyclosporine in 10 patients, CSA+mycophenolate mofetil in 16 patients... We conclude that use of TCR αβ depleted haploidentical transplantation ensures a high engraftment rate; good immune reconstitution; low incidence of significant aGvHD, and acceptable posttransplantation morbidity in children with a range of PIDs and should be considered in children with PIDs lacking an HLA-matched donor, when urgent HSCT is indicated.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1369;    
    SCD represents a chronic and multisystemic disease with a high morbidity and mortality. Results with MSD transplant are excellent; therefore it is important to refer these patients to centers with experience and promptly assess the indication of HSCT.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, tacrolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1364;    
    The outcome of our center, the largest HCST series in Spain is similar to the international cohort and confirms the role of HLA-identical sibling transplantation for children with SCD. Since 2015 we improved our results, with less toxicity and without mortality.
  • ||||||||||  tacrolimus / Generic mfg., sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_1216;    
    The association of both calcineurin-inhibitors or sirolimus to PTCy and MMF gives similar results in terms of aGvHD and cGvHD incidence after unmanipulated haplo-SCT. Patients receiving calcineurin-inhibitor-based GvHD prophylaxis showed higher incidence of endothelial complications.
  • ||||||||||  Ovastat (treosulfan) / Medac, melphalan / Generic mfg.
    [VIRTUAL] IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE (ePoster Area) -  Feb 8, 2020 - Abstract #EBMT2020EBMT_858;    
    In pts with hematological relapse at the time of HSCT Melphalan (Mel, 100mg/m2) before Treo/Flu was added to induce aplasia... Although the number of pts is small and the follow-up short, this analysis shows the efficacy and feasibility of early allogeneic HSCT in molecular relapse for NPM positive AML pts and should be confirmed in a greater number of pts.
  • ||||||||||  Ovastat (treosulfan) / Medac
    Preclinical, Journal:  In Vitro Study of the Enzymatic and Nonenzymatic Conjugation of Treosulfan with Glutathione. (Pubmed Central) -  Feb 7, 2020   
    Treosulfan does not undergo either spontaneous or enzymatic conjugation with GSH at a noticeable rate. The result indicates that the clearance of treosulfan is independent of glutathione S-transferase activity, GSH stores, and co-administration of drugs utilizing the GSH metabolic pathway.
  • ||||||||||  Natesto (testosterone) / Acerus, Aytu BioScience, Medac
    The Effect of Natesto on Spermatogenesis, Reproductive Hormones, and Hypogonadal Symptoms. A Phase IV Study (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_1693;    
    This phase IV clinical trial demonstrated that Natesto increased serum T, improved hypogonadal symptoms, maintained gonadotropins, testis volume, intratesticular testosterone and semen parameters. Natesto, and other short acting forms of testosterone therapy may help hypogonadal men maintain fertility.
  • ||||||||||  Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker:  I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) -  Jan 22, 2020   
    P2,  N=1920, Recruiting, 
    T-cell depletion reduces the risk of GVHD and the need for steroid therapy, which is especially challenging in patients with diabetes. Trial primary completion date: Dec 2020 --> Dec 2025
  • ||||||||||  T-Cell Replete Haploidentical Bone Marrow Transplantation and Post-Transplant Cyclophosphamide for Patients with Inborn Errors (World Center Marriott - Palms & Cypress Foyers) -  Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1086;    
    Chemotherapy based conditioning and haploidentical HSCT with pTCy was safe and resulted in good disease free survival in this cohort of patients with inborn errors in the absence of relevant GHVD. These results compare well with outcomes achieved with matched donors in similar cohorts of patients, but larger multi-center studies are warranted to further evaluate this approach.
  • ||||||||||  Ovastat (treosulfan) / Medac, spanlecortemlocel (MGTA-456) / Magenta Therap, busulfan / Generic mfg.
    High Dose Hematopoietic Stem Cell Transplantation Leads to Rapid Neural and Peripheral Disease Cross-Correction Via Robust Hematopoietic and Microglia Recovery (World Center Marriott - Palms & Cypress Foyers) -  Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1083;    
    At 1-16 weeks post-HSCT, transplant of increasing doses of total bone marrow cells following myeloablative busulfan conditioning led to a dose-dependent increase microglial engraftment (26-fold for 10x106 cells vs 0.3x106 cells, p<0.01), with 91-99% peripheral donor chimerism...In contrast, transplant of 10x106 cells into mice conditioned with a myeloablative dose of treosulfan, an agent that does not permit brain microglial engraftment (Figure A), did not correct CNS defects (Figure B-C), suggesting that donor engraftment in the CNS is required for disease correction...We show that high dose HSCT leads to improved disease correction, including normalization of behavioral outcomes, via robust engraftment. High dose cell therapies, like MGTA-456, may rapidly and durably resolve peripheral and neurologic disease in patients with IMDs and other neurodegenerative diseases caused by defective microglia.
  • ||||||||||  Ovastat (treosulfan) / Medac, Medexus
    Enrollment closed:  Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases (clinicaltrials.gov) -  Jan 14, 2020   
    P2,  N=100, Active, not recruiting, 
    High dose cell therapies, like MGTA-456, may rapidly and durably resolve peripheral and neurologic disease in patients with IMDs and other neurodegenerative diseases caused by defective microglia. Recruiting --> Active, not recruiting